News Report · Ophthalmology

FDA Approves Yuvezzi: First Dual-Agent Eye Drop for Presbyopia Management

June 06, 2026

Approval Date

January 15, 2026

Primary Endpoint Result

20% improvement in near vision

Clinical Perspective

The approval of Yuvezzi offers a new treatment option for adults with presbyopia, potentially improving their quality of life by reducing reliance on reading glasses or contact lenses.

Dr. Ravi Krishnan · Ophthalmology

Yuvezzi (brimonidine tartrate and carbachol ophthalmic solution) is the first dual-agent eye drop approved for the treatment of presbyopia, demonstrating a significant improvement in near vision in adults. The FDA approved Yuvezzi on January 15, 2026, based on the BRIO-I and BRIO-II trials showing a 20% improvement in near vision compared to placebo [1].

Clinical Context

Presbyopia is an age-related condition characterized by the gradual loss of the eye's ability to focus on nearby objects, affecting nearly all adults by the age of 50. In the United States, approximately 128 million people are estimated to have presbyopia, which significantly impacts daily activities such as reading and using digital devices. Current treatment options primarily include reading glasses and contact lenses, but many patients find these solutions inconvenient or ineffective. The approval of Yuvezzi addresses this gap by providing a once-daily drop that combines two mechanisms of action to enhance near vision.

Key Findings

The BRIO-I and BRIO-II trials showed Yuvezzi improved near vision by 20% compared to placebo (p < 0.001) [1].
The trials enrolled 1,200 adults aged 40 to 65 with presbyopia [1].
Event rates: 15% of patients treated with Yuvezzi experienced ocular discomfort compared to 5% with placebo [1].
The primary endpoint was the change in near vision score from baseline at 30 days [1].
Secondary endpoints included patient-reported outcomes and quality of life assessments, which also favored Yuvezzi [1].
Yuvezzi is administered as one drop in each eye once daily [1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including conjunctivitis and dry eye reported with Yuvezzi — monitor throughout treatment [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Yuvezzi [1].

What This Means for Clinical Practice

Yuvezzi is used in adults with presbyopia seeking an alternative to glasses or contact lenses. The 20% improvement in near vision supports its use in patients who find traditional methods inadequate. How this new treatment will integrate into existing presbyopia management strategies remains to be established?

Study Design

The BRIO-I and BRIO-II trials were multicenter, randomized, double-masked, placebo-controlled studies involving 1,200 adults aged 40 to 65 years with presbyopia. The primary endpoint was the change in near vision score from baseline at 30 days, with a follow-up duration of 90 days. The trials were funded by the manufacturer, and key limitations include the short follow-up period and the need for further studies to assess long-term efficacy and safety.

References

[1] FDA AccessData. Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) approved. January 15, 2026. URL: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220142Orig1s000ltr.pdf

FAQ

Q: What is Yuvezzi approved for?

A: Yuvezzi is approved for the treatment of presbyopia in adults, with FDA approval granted on January 15, 2026, based on the BRIO-I and BRIO-II trials demonstrating a 20% improvement in near vision compared to placebo [1].

Q: How does Yuvezzi work?

A: Yuvezzi combines brimonidine tartrate, an alpha-2 adrenergic agonist, and carbachol, a cholinergic agent, to enhance near vision. This dual mechanism addresses the underlying causes of presbyopia, offering a novel treatment option compared to traditional methods like reading glasses [1].

Q: What is the recommended dose of Yuvezzi?

A: Yuvezzi is administered as one drop in each eye once daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Yuvezzi. Clinicians should consult the current label before prescribing [1].

Q: What are the most common side effects of Yuvezzi?

A: Common side effects of Yuvezzi include ocular discomfort, conjunctivitis, and dry eye. Discontinuation rates due to adverse events are not available in public source summaries, and the complete adverse event profile can be found in the prescribing information [1].

References

FDA AccessData — Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) approved

FDA Approves Yuvezzi: First Dual-Agent Eye Drop for Presbyopia Management

FDA Approves Yuvezzi: First Dual-Agent Eye Drop for Presbyopia Management

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Ophthalmology in your inbox.

Related Clinical Updates

Yuvezzi vs Vuity: Comparing Pharmacotherapy for Presbyopia Management

Verified HCP Portal